Molecular Cancer (MC) is a scholarly journal dedicated to publishing research in the field of Medicine. BioMed Central is the publisher of this esteemed journal. and its abbreviated form is Mol Cancer.
Molecular Cancer promotes the exchange of ideas, concepts and findings in any area of cancer and related biomedical science, from a molecular point of view. Molecular Cancer is interested in articles from basic, translational and clinical research, opening new avenues for the understanding, prevention, diagnosis and treatment of cancer. Topics of interest include, but are not limited to: cell and tumor biology, angiogenesis, animal models, metastasis, cancer antigens and the immune response to them, cellular signalling and molecular biology, epidemiology, genetic and molecular profiling of cancer and molecular targets, cancer stem cells, DNA damage and repair, cell cycle, apoptosis, molecular virology and vaccine- and antibody-based cancer therapies.
| Journal title | Molecular Cancer (MC) |
| Abbreviation | Mol Cancer |
| Online ISSN | 1476-4598 |
| Publisher Name | BioMed Central |
| Editor-in-chief | Cristophe Nicot |
| Subject Category | Medicine |
Molecular Cancer Abbreviation : ISO Journal abbreviation refers to the shortened form or acronym used to represent the full title of a scholarly journal. The ISO4 Abbreviation of Molecular Cancer Journal is Mol Cancer.
The Ranking of Molecular Cancer in 2026 is 96. Ranking systems aim to provide an indication of a journal's quality, influence, and prestige within a specific field or discipline.
The Impact Factor of Molecular Cancer in 2026 is 33.1. it is all calculated by Clarivate, which means how many times a particular citation has been published in the past two years.
The SCImago of Molecular Cancer in 2026 is 8.703. It is measured by the number of citations which are made by the particular journals, and the journal from where the citations arrived from.
The H-Index of Molecular Cancer in 2026 is 171. The H-index is calculated on how many times a particular author is cited and the number of published papers that a particular author has.
The Quartile of Molecular Cancer is Q1. A quartile has three points, which are the upper quartile, median, and lower quartile. The main motive of the quartile is to calculate the interquartile range, that resembles the changes across the median.
The Molecular Cancer is indexed in (Indexing details)
| PubMed | Scopus | Web of Science | UGC | Embase | DOAJ |
|---|---|---|---|---|---|
| ✅ | ✅ | ✅ | ✅ | ✅ | ✅ |
Indexing services aim to make it easier for researchers, scholars, and readers to discover and access articles from various journals within a specific field or discipline.
| Abbreviation | Mol Cancer |
| Access type | Hybrid |
| Impact Factor | 33.1 |
| SJR | 8.703 |
| SNIP | 5.740 |
| Ranking | 96 |
| CiteScore | 64.9 |
| H-Index | 171 |
Molecular Cancer Processing/Submission Fee : Article submission/Processing fees (APC), also known as manuscript Publication fees or processing fees (APC), are charged by journals to authors for submitting/publishing their research papers/article.
The APC/Submission (Publication) Fee of Molecular Cancer is 4890.00 USD
Molecular Cancer Call for paper : Molecular Cancer invites original research contributions for consideration of publication in Molecular Cancer journal.
Journal seeking submissions in the broad areas of Medicine that align with journal's focus on Medicine.
for details about call for paper please visit to the official website of the journal to check the details about call for papers.
Publishing in Molecular Cancer involves the following steps:
Yes, the Molecular Cancer journal is indexed in PubMed.
Yes, the Molecular Cancer journal is indexed in Scopus.
Yes, the Molecular Cancer journal is indexed in UGC.
No, the Molecular Cancer journal is not indexed in Index copernicus.
No, Molecular Cancer journal is not a predatory journal.
The Impact Factor of the Molecular Cancer is 33.1.
The Ranking of the Molecular Cancer is 96.
Yes the Molecular Cancer (MC) journal is a peer-reviewed journal.
Yes the Molecular Cancer journal is a peer-reviewed journal and good to publish your paper.
Molecular Cancer (MC) is a scholarly journal dedicated to publishing research in the field of Medicine. BioMed Central is the publisher of this esteemed journal.
Yes, Molecular Cancer is a open access (Hybrid) journal.